ClinicalTrials.gg
Active, not recruitingNCT02911103Updated Nov 12, 2026

Deep Brain Stimulation Surgery for Focal Hand Dystonia

A Phase 1/2 interventional study of DBS surgery and Medtronic Activa Rechargeable System in Dystonia, Focal Dystonia and Musician's Dystonia, sponsored by National Institute of Neurological Disorders and Stroke (NINDS). Active, not recruiting at 1 site in United States. Open to participants aged 22 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Institute of Neurological Disorders and Stroke (NINDS) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
22 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Dystonia by National Institute of Neurological Disorders and Stroke (NINDS) — 1 open to participants now, 2 under way, none of them phase 3. Dystonia · National Institute of Neurological Disorders and Stroke (NINDS).

Enrollment
15th of 15
5 · median 24
Started
2018
the only one that year
Phase 1/2
3 of 32
none open now
Registered
30th of 32
by date

Among the 32 studies in Dystonia by National Institute of Neurological Disorders and Stroke (NINDS), this one is the 15th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 3 in phase 1/2, and was the 30th registered.

Dystonia

213 studies on the registry are indexed under Dystonia; 54 are open to participants now.

Browse Dystonia studies →

Open to participants now

1 of the 32 studies in Dystonia by National Institute of Neurological Disorders and Stroke (NINDS) is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 41 Dystonia studies recruiting now, 19 (46%) set no upper age limit and 10 (24%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 22 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Dystonia by National Institute of Neurological Disorders and Stroke (NINDS), or all of them as a file.
02

Study summary

Researchers want to test a procedure called deep brain simulation (DBS) to treat focal hand dystonia (FHD). A device called a neurostimulator is placed in the chest. It is attached to wires placed in brain areas that affect movement. Stimulating these areas can help block nerve signals that cause abnormal movements.

Objectives:

To test DBS as treatment for FHD. To learn about brain and nerve cell function in people with dystonia.

Eligibility:

People ages 18 and older with severe FHD who have tried botulinum toxin treatment at least twice

Design:

Participation lasts 5 years.

Participants will be screened with:

Medical history

Physical exam

Videotape of their dystonia

Blood, urine, and heart tests

Brain MRI scan

Chest X-ray

Neuropsychological tests: answering questions, doing simple actions, and taking memory and thinking tests.

Hand movement tests

Participants will have surgery: A frame fixes their head to the operating table. A small hole is made in the skull. Wires are inserted to record brain activity and stimulate the brain while they do simple tasks. The wires are removed and the DBS electrode is inserted into the hole. The neurostimulator is placed under the skin of the chest, with wires running to the electrode in the brain. They will have CT and MRI scans during surgery.

Participants will recover in the hospital for about 1 week.

The neurostimulator will be turned on 1 4 weeks after discharge. Participants will have regular visits until the study ends. Visits include:

Checking symptoms and side effects

MRI

Movement, thinking, and memory tests

If the neurostimulator s battery runs out, participants will have surgery to replace it.

Read the detailed description

Objectives

To confirm the safety and possible trends toward efficacy of thalamic deep brain stimulation (DBS) targeting the ventralis oralis anterior/ventralis oralis posterior (VOA/VOP) nuclear complex in the treatment of subjects with focal hand dystonia (FHD); and to study the electrophysiologic properties of neurons in the VOA/VOP complex. DBS is FDA approved for Parkinson's disease, Essential tremor, Dystonia (humanitarian exemption), Obsessive- Compulsive disorder (humanitarian exemption) but not for focal hand dystonia.

Study population

Five adults with focal hand dystonia will be studied.

Design

This is a pilot study of 5 subjects with severe intractable FHD whose activities of daily living and quality of life are severely impaired. They will be recruited from our clinic and from referring practices. The subjects will undergo unilateral VOA/VOP DBS implantation, followed by programming to optimal parameters. The subjects will be followed at monthly intervals for 3 months, then every 3 months for 2 years, and then every 6 months until 5 years from the start. The safety of the procedure will be the primary outcome of the study. Trends toward efficacy will be assessed in several secondary outcomes, the most important ones being the change in dystonia severity and a quality of life scores. The electrophysiologic features of the motor ventral thalamic neurons will be recorded intraoperatively.

Outcome measures

Primary

-Number and severity of adverse events in the 5-year follow-up period.

Secondary

  • Upper extremity sub-score of the Burke-Fahn-Marsden (BFM) scale and Arm Dystonia Disability Scale (ADDS) at baseline and every follow up visit
  • For subjects with FHD type musician's dystonia: Tubiana and Chamagne scale at every follow up visit
  • For subjects with FHD type Writer's cramp: Writer's Cramp Impairment Scale
  • Improvement on patient reported outcomes evaluated by the SF-12 Health Status Survey at baseline and at every follow up visit
  • Neuropsychological evaluation at baseline, 3 and 12 months post DBS surgery
  • Dose of botulinum toxin injection required at baseline, 1 and 5 years.

Exploratory

  • Intraoperatory electrophysiologic characteristics of the motor ventral thalamic neurons
  • Local field potentials and their response to stimulation (in participants with implanted pulse generator capable of sensing capabilities)
03

Conditions studied

  • Dystonia
  • Focal Dystonia
  • Musician's Dystonia

Keywords

  • Electrophysiology
  • Neurosurgery
  • Dystonia
  • Deep Brain Stimulation
04

Who can participate

Ages eligible
22 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • FHD diagnosed by a neurologist
  • BFM upper extremity subscore of 3 or more (score range 0 to 4) or ADDS difficulty of performing score equal to or more than 3.
  • Patients must score 3 or below on the Tubiana and Chamagne scale or inability to perform at the concert level or patients must score a rating of "severe" on at least one item, impacting the patient s employment or essential activities on the Writer s Cramp Impairment scale.
  • Symptoms causing significant impairment in quality of life and work or daily activities by patient self-assessment and SF12 scale, as reported by subjects. The subjects should be severely impaired in at least one of the following domains: handwriting, typing or playing an instrument. The impairment needs to have affected employment, manifested by substantive change in, or loss of, employment or career of choice.
  • All patients must have failed or achieved inadequate benefit (continuing functional impairment) with at least two trials of botulinum toxin treatments.
  • Women of childbearing age will have to agree to use methods for the first 3 post operative months.

Exclusion criteria

EXCLUSION CRITERIA:

  • Subjects younger than 22 years old.
  • MRI findings that would make participation and surgery unsafe (such as tumor or other space occupying lesion, stroke, hemorrhage or hematoma, edema, hydrocephalus, abscess) and MRI findings that would confound study outcomes (such as iron deposits in the basal ganglia, demyelinating disease, traumatic brain injury, structural or developmental abnormality, moderate or severe white matter hyperintensities).
  • Subjects with prior brain surgery
  • Pregnant or nursing women as safety of DBS has not been established in this group.
  • Presence of a more widespread neurologic syndrome with the dystonia being part of it, and/or dystonia caused by an ongoing etiology, such as tardive dystonia associated with ongoing psychotropic treatment or an inherited neurodegenerative syndrome associated with intractable dystonia
  • Intellectual disability as measured by the estimated General Ability Index (GAI) of the Wechsler Adult Intelligence Scale 4th Edition (WAIS-IV), which would render the participant not able to provide or to comply with the study procedures (estimated GAI less than 70)
  • Dementia as evidenced by formal neuropsychological evaluation and Mattis Dementia Rating Scale-2 (DRS-2) score below 128.
  • Depressed subjects as determined by the neuropsychology or psychiatry screen, including Beck Depression Inventory (BDI) and psychiatric evaluation. Subjects scoring above 20 on the BDI or exhibiting moderate or severe active depression will be excluded
  • Subjects with uncontrolled co-existing medical conditions: uncontrolled systemic hypertension with values above 170/100; active heart disease needing immediate intervention; active respiratory disease needing immediate intervention; uncorrected coagulation abnormalities; any condition that would render the patient unable to safely cooperate with the surgery and study tests as judged by the screening physician
  • Presence of a to undergo a brain MRI

    • Metal in the body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have;
    • Uncomfortable in small closed spaces (have claustrophobia) such that the participant will be uncomfortable in the MRI machine;
    • Unable to lay comfortably flat on their back for up to one hour in the MRI scanner;
  • Subjects who require diathermy
  • Subjects who require post-op MRIs with full body coil

    -- Subjects with an active systematic infection

  • Subjects who are immune-compromised
  • Subjects who are on anticoagulation therapy that would preclude their ability to undergo the implant procedure
  • Subjects who are allergic or have shown to any materials of the neurostimulation system which may come in contact with the body
  • Subjects that cannot appoint a Durable power of attorney (DPA)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Active

    single arm study

    Procedure: DBS surgery · Device: Medtronic Activa Rechargeable System

Interventions

  • ProcedureDBS surgery

    Unilateral thalamic DBS therapy

  • DeviceMedtronic Activa Rechargeable System

    Used for diagnostic purposes.

06

What researchers measure

Primary outcomes

  1. To confirm the safety of VOA/VOP thalamic DBS in FHD

    Number and severity of adverse events in the 5-year follow-up period.

    Time frame: 5 years

Secondary outcomes

  1. Neuropsychological Evaluation

    To perform a neuropsychological evaluation at baseline, 3 and 12 months post DBS surgery of the VOA/VOP complex in subjects with FHD

    Time frame: 5 years

  2. To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in clinical improvement of severe intractable FHD

    Burke-Fahn-Marsden (BFM) scale and Arm Dystonia Disability Scale (ADDS) at baseline and every follow up visit

    Time frame: 5 years

  3. To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in improved patient reported outcomes

    Neuropsychological evaluation at baseline, 3 and 12 months post DBS surgery

    Time frame: 5 years

  4. To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in improvement of severe intractable FHD in subjects with musician s dystonia

    For subjects with FHD type Musician s Dystonia: Tubiana and Chamagne scale at every follow up visit

    Time frame: 5 years

  5. To determine if thalamic DBS targeting the VOA/VOP nuclear complex results in improvement of severe intractable FHD in subjects with Writer s cramp

    For subjects with FHD type writer s cramp: Writer s Cramp Impairment Scale

    Time frame: 5 years

  6. To evaluate the botulinum toxin dose required for the treatment of FHD at baseline and 1 and 5 years after DBS therapy of the VOA/VOP complex

    Dose of Botulinum Toxin at 1 and 5 years

    Time frame: 5 years

07

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
08

References and documents

Individual participant data

Plan to share: Undecided — It has not been determined whether sharing IPD will be feasible for this study.

09

Timeline

7 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Feb 2029, 132 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 22, 2016
StartActual
Jan 17, 2018
Primary completionEst.
Feb 2, 2029
CompletionEst.
Feb 2, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
7 updates, last Nov 12, 2026
Show all 7 updates
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 9, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 5, 2026
    Minor edits only
    + 1 other change: description
  4. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  5. Oct 16, 2026
    Minor edits only
    + 1 other change: description
  6. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  7. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02911103
Responsible party
Sponsor
First posted
Sep 22, 2016
Start date
Jan 17, 2018
Primary completion
Feb 2, 2029 (estimated)
Completion
Feb 2, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Debra J Ehrlich, M.D.
principal investigator · National Institute of Neurological Disorders and Stroke (NINDS)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion